BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 10365121)

  • 1. Serum cholecystokinin and neurotensin during follow-up of pancreas, prostate and medullary thyroid tumors.
    Pichon MF; Coquin G; Fauveau C; Rey A
    Anticancer Res; 1999; 19(2B):1445-50. PubMed ID: 10365121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Usefulness of serum calcitonin, CEA and AFP assays in the early detection of medullary thyroid carcinoma relapse].
    Łacka K; Michałek K; Majewski P
    Wiad Lek; 2002; 55(7-8):394-403. PubMed ID: 12428567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating calcitonin and carcinoembryonic antigen m-RNA detected by RT-PCR as tumour markers in medullary thyroid carcinoma.
    Bojunga J; Dragan C; Schumm-Draeger PM; Usadel KH; Kusterer K
    Br J Cancer; 2001 Nov; 85(10):1546-50. PubMed ID: 11720443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abnormal carcinoembryonic antigen levels and medullary thyroid cancer progression: a multivariate analysis.
    Machens A; Ukkat J; Hauptmann S; Dralle H
    Arch Surg; 2007 Mar; 142(3):289-93; discussion 294. PubMed ID: 17372055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic variables and calcitonin in medullary thyroid cancer.
    Clark JR; Fridman TR; Odell MJ; Brierley J; Walfish PG; Freeman JL
    Laryngoscope; 2005 Aug; 115(8):1445-50. PubMed ID: 16094121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chromogranin A and biochemical progression-free survival in prostate adenocarcinomas submitted to radical prostatectomy.
    Alessandro S; Vincenzo G; Maria AG; Stefano S; Alessandro G; Salvatore M; Vincenzo T; Franco DS
    Endocr Relat Cancer; 2007 Sep; 14(3):625-32. PubMed ID: 17914093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
    Béhé M; Behr TM
    Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of surgical treatment of sporadic medullary thyroid carcinoma following routine measurement of serum calcitonin.
    Mirallié E; Iacobone M; Sebag F; Henry JF
    Eur J Surg Oncol; 2004 Sep; 30(7):790-5. PubMed ID: 15296996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
    Chen C; Chen LQ; Yang GL; Li Y
    Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Markers of undiagnosed incidental cancer in comparison with clinical prostatic cancer.
    Ogawa A; Yoshida A; Kanda T; Sugihara S; Suzuki T; Tamura J; Kobayashi I; Nakazato Y
    J Med; 2000; 31(1-2):101-10. PubMed ID: 10998759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum calcitonin in small cell carcinoma of the prostate.
    Sim SJ; Glassman AB; Ro JY; Lee JJ; Logothetis CJ; Liu FJ
    Ann Clin Lab Sci; 1996; 26(6):487-95. PubMed ID: 8908318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromogranin A: an additional tumor marker for postoperative recurrence and metastases of medullary thyroid carcinomas?
    Franke WG; Pinkert J; Runge R; Bredow J; Wunderlich G; Koch R
    Anticancer Res; 2000; 20(6D):5257-60. PubMed ID: 11326706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased serum level of sialyl Lewis(x) antigen in blood from the tumor drainage vein in patients with non-polypoid growth type of colorectal cancer.
    Nakagoe T; Sawai T; Tsuji T; Jibiki M; Ohbatake M; Nanashima A; Yamaguchi H; Kurosaki N; Yasutake T; Ayabe H; Arisawa K
    J Exp Clin Cancer Res; 2001 Mar; 20(1):85-90. PubMed ID: 11370835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.
    Guadagni F; Kantor J; Aloe S; Carone MD; Spila A; D'Alessandro R; Abbolito MR; Cosimelli M; Graziano F; Carboni F; Carlini S; Perri P; Sciarretta F; Greiner JW; Kashmiri SV; Steinberg SM; Roselli M; Schlom J
    Cancer Res; 2001 Mar; 61(6):2523-32. PubMed ID: 11289125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of histologic type and smoking status on interpretation of serum carcinoembryonic antigen value in non-small cell lung carcinoma.
    Okada M; Nishio W; Sakamoto T; Uchino K; Yuki T; Nakagawa A; Tsubota N
    Ann Thorac Surg; 2004 Sep; 78(3):1004-9; discussion 1009-10. PubMed ID: 15337038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
    Soga N; Onishi T; Arima K; Sugimura Y
    Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
    Roobol MJ; Kranse R; de Koning HJ; Schröder FH
    Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medullary thyroid carcinoma presenting with an initial CEA elevation.
    Abraham D; Delbridge L; Clifton-Bligh R; Clifton-Bligh P; Grodski S; Robinson BG; Messina M; Sidhu S
    ANZ J Surg; 2010 Nov; 80(11):831-3. PubMed ID: 20969693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.